Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 150


The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.

Sallman DA, List A.

Blood. 2019 Mar 7;133(10):1039-1048. doi: 10.1182/blood-2018-10-844654. Epub 2019 Jan 22. Review.


Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.

Lee JH, List A, Sallman DA.

Eur J Haematol. 2019 Mar;102(3):203-209. doi: 10.1111/ejh.13207. Epub 2019 Jan 16. Review.


Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.


Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E.

Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19.


A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.

List A, Ebert BL, Fenaux P.

Leukemia. 2018 Jul;32(7):1493-1499. doi: 10.1038/s41375-018-0029-9. Epub 2018 Jan 30. Review.


Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.

Mei Y, Zhao B, Basiorka AA, Yang J, Cao L, Zhang J, List A, Ji P.

Leukemia. 2018 Apr;32(4):1023-1033. doi: 10.1038/leu.2017.326. Epub 2017 Nov 16.


ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. No abstract available.


Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.


SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.

Sallman DA, Tanaka TN, List A, Bejar R.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25. Review.


Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A.

Haematologica. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5.


Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

Talati C, Sallman D, List A.

Semin Hematol. 2017 Jul;54(3):159-166. doi: 10.1053/j.seminhematol.2017.06.003. Epub 2017 Jun 22. Review.


TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16.


Erythropoietin Receptor Signaling and Lipid Rafts.

McGraw K, List A.

Vitam Horm. 2017;105:79-100. doi: 10.1016/bs.vh.2017.02.002. Epub 2017 Mar 23. Review.


Pattern classification of EEG signals reveals perceptual and attentional states.

List A, Rosenberg MD, Sherman A, Esterman M.

PLoS One. 2017 Apr 26;12(4):e0176349. doi: 10.1371/journal.pone.0176349. eCollection 2017.


Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R.

Leukemia. 2017 Jun;31(6):1391-1397. doi: 10.1038/leu.2017.33. Epub 2017 Jan 23.


Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S.

Leukemia. 2017 Oct;31(10):2172-2180. doi: 10.1038/leu.2017.21. Epub 2017 Jan 18.


Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'.

Sallman DA, Komrokji R, List A, Padron E.

Leukemia. 2017 Mar;31(3):767-768. doi: 10.1038/leu.2016.257. Epub 2016 Oct 14. No abstract available.


Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience.

Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S53-6. doi: 10.1016/j.clml.2016.02.022.


Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome.

Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S44-8. doi: 10.1016/j.clml.2016.02.017.


Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.

Sallman DA, Cluzeau T, Basiorka AA, List A.

Front Oncol. 2016 Jun 16;6:151. doi: 10.3389/fonc.2016.00151. eCollection 2016. Review.

Supplemental Content

Loading ...
Support Center